major surpris focu
deliv solid earn major surpris follow
januari pre-announce pleas see holog check box
cyno in-lin major tax benefit view key theme
remain around new product contribut sale intern growth
cynosur acquisit breast health rev increas
y/i organ believ servic intern growth new product support
achiev lsd growth diagnost rev increas y/i
organ despit outsiz work-day headwind led double-digit underli
growth molecular test continu take share panther system
fusion/vir load support msd growth segment gyn surgic
rev weaker expect organ growth prove
disrupt quarter manag focus improv execut
final intern grew organ y/i anoth strong show
maintain revenu guidanc rais ep guidanc account
mostli tax reform new rang midpoint
repres growth y/i continu see number potenti upsid driver
guidanc includ new product capit deploy leverag
cynosur rev think reassur see hit expect
revenu million busi clearli seen disrupt
follow period signific sale forc turnov acquisit
outsiz impact sale given capit equip natur busi
manag reiter septemb quarter bottom march
quarter manag note season weak quarter capit sale
believ segment could potenti still grow q/q given tailwind new
product sale forc execut model cynosur revenu
million flat q/q forecast revenu growth ex-fx believ
sentiment cynosur perform bottom concurr
stronger longer thesi intact reiter overweight rate
quarterli annual ep usd
consensu number thomson reuter
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight believ grow
stronger longer driven longer
mammographi tail mdx growth panther
myosur tuck-in new product launch
could drive modest upsid revenu
mdx gyn surgic busi continu
drive outsiz growth new product launch
add modestli growth upsid case
reflect upsid earn power
penetr rate us mammographi
busi slow faster expect downsid
case reflect downsid earn
power
deliv solid earn major surpris follow januari
pre-announce pleas see holog check box
cyno in-lin major tax benefit view key theme remain around
new product contribut sale intern growth
cynosur acquisit breast health rev increas y/i organ
believ servic intern growth new product support achiev lsd growth
diagnost rev increas y/i organ despit
outsiz work-day impact led double-digit underli growth molecular test
continu take share panther system fusion/vir load support
msd growth segment gyn surgic rev weaker
expect organ growth prove disrupt quarter
manag focus improv execut final intern grew
guidanc rais ep guidanc account mostli tax reform new rang
midpoint repres growth y/i continu see
number potenti upsid driver guidanc includ new product contribut
capit deploy leverag
cynosur rev think reassur see hit expect
revenu million busi clearli seen disrupt follow
period signific sale forc turnov acquisit outsiz
impact sale given capit equip natur busi manag reiter
septemb quarter bottom march quarter manag note
season weak quarter capit sale believ segment could
potenti still grow q/q given tailwind new product sale forc execut
model cynosur revenu million flat q/q forecast
revenu growth ex-fx believ sentiment cynosur perform
bottom concurr stronger longer thesi intact reiter
overweight rate
maintain revenu forecast see upsid potenti
new product ep guidanc increas due tax reform
midpoint embed revenu guidanc expect fx tailwind
estim combin cynosur acquisit blood screen divestitur
would contribut growth addit estim fewer sell day
headwind top line revenu growth assumpt
growth assumpt segment
breast previous guid low single-digit segment growth
driven strength servic revenu intern busi new product
includ affirm brevera cfo mcmahon note feel better guidanc
follow stronger show lsd growth consist
expect support recent mqsa data pleas see report
diagnost expect low mid single-digit organ growth
exclud blood screen panther major driver growth segment
expand menu includ fulli approv us viral load categori pleas
see report final viral load approv expand
instrument believ could differenti consolid test onto
platform growth anticip sustain strong momentum
blood screen transit servic anticip drive revenu million
medic aesthet cynosur previous expect double-digit growth
embed guidanc stabil fulli product sale forc new
product also expect drive growth peg organ growth
organ total growth impli million annual revenu keep
mind revenu declin includ declin
gyn surgic given weaker result moder commentari
around mid single-digit segment growth segment anticip
benefit market expans effort myosur new product
stabil novasur intern busi said believ
competit new leadership team could continu pressur near-term result vs
long-term growth trajectori
ep guidanc rais midpoint
previous impli growth remind compani
margin declin significantli follow blood screen divestitur cynosur
acquisit expect see margin improv driven oper
effici initi compani expect non-gaap tax rate year
previous due tax reform well dilut share count
million guidanc assum capit alloc asid call convert
note guidanc impli revenu growth lead
revenu rang million estim organ growth guidanc
compani expect adjust ep rang
breast health deliv organ growth driven combin resili us
placement servic growth new product intern share gain
improv convict segment grow low single-digit
compani approach penetr instal base compani
conserv tone around placement opportun compani exhaust
multi-ord placement opportun larger hospit leav smaller commun
hospit custom gener price sensit order size smaller
make placement opportun harder come manag roll
addit tier product help penetr smaller site unlik
cycl believ help extend tail placement eas concern
potenti mammographi cliff
specif breast imag compani report million revenu
y/i ex-fx driven solid us result strength intern us breast
busi declin y/i ex-fx howev intern busi grew ex-
fx along stronger sale system growth driven servic new
product revenu remind recent launch brevera expect
contribut growth addit compani note amid
competit environ gain market share put growth
perspect chart note estim placement end
total estim penetr amongst exist
custom base stabl sequenti trend placement consist fda mqsa
data publish describ placement rate larg steadi
mammographi upgrad cycl drive growth servic revenu due higher price
remind saw acceler ffdm placement rate earli
acceler driven factor
includ reimburs
mammographi addit renew invest sale market ge
siemen back launch new unit keep mind calendar fourth
quarter year typic season weak given time rsna
confer loss sell week
unit placement unit barclay holog inc
quarterli placement ffdm unit
monthli placement ffdm unit
made signific progress de-lever follow cynosur
acquisit reach point capit deploy repres real
opportun compani exit quarter net debt/ebitda ratio
expect declin end follow portfolio chang
compani leverag remain point pursu addit capit
deploy believ compani priorit tuck-in acquisit absent
would expect compani pay debt repurchas share believ gyn
placementstot unitsdigit unitsquarterli unit barclay holog inc
net debt ttm ebitda
surgic diagnost like area could augment
diagnost point care poc notabl gap compani portfolio
critiqu poc market mani compani
success gener profit said point care one
fastest grow area coverag sustain secular tailwind relat
consumer healthcar would natur cross-sel opportun
hospit touch point panther mdx system
gyn surgic could also attract area tuck-in addit product
 ad product gyn surgic portfolio would better leverag gyn
sale forc third product market ob/gyn
compani post strong intern growth third consecut quarter
prove commerci effort abroad bear fruit constant currenc
basi exclud blood screen cynosur total intern revenu increas
y/i strength led breast health constant currenc
diagnost despit impact fewer sell day quarter
encourag strength compani molecular diagnost busi driven
strength panther placement compani women health aptima assay
manag previous note viral load revenu remain small compani
encourag growth seen intern
revenu increas y/i million exclud result blood
screen busi success divest cynosur
headwind sell day organ revenu grew around y/i quarter blood
screen contribut million cynosur ad million new product
contribut revenu quarter sequenti quarter
growth follow chang manag late compani post anoth
strong quarter intern growth ex-portfolio chang
growth specif strong sale diagnost y/i ex-fx breast
debt ebitda barclay holog inc
revenu organ growth
compani saw healthi growth breast diagnost cynosur
came line gyn surgic weaker forecast
diagnost revenu segment revenu grew y/i ex-fx
adjust blood screen divestitur around ex-sel day
chang molecular diagnost increas y/i ex-fx driven increas market
share util panther system notabl diagnost grew
intern ex-fx driven continu panther placement new product
introduct includ viral load compani full menu sexual health
viral load respiratori assay market global total panther
place diagnost custom includ unit state
remind compani complet sale blood screen busi
januari cytolog perinat revenu increas ex-fx
breast revenu revenu grew y/i ex-fx despit increas
market penetr geniu mammographi placement remain strong
quarter call mcmillan note strong placement eas concern
potenti mammographi cliff ceo mcmillan note new mammographi
system repres almost system place quarter addit
strong servic revenu million quarter despit workday
headwind driven larger instal base compani start see
contribut affirm biopsi system softer breast health revenu
ex-fx partial off-set anoth strong quarter intern revenu
ex-fx estim compani us placement quarter
estim bring cumul placement
cynosur rev holog close acquisit cynosur march
busi contribut million revenu quarter sale
improv sequenti though y/i ex-fx tough comp
manag continu believ revenu bottom believ
result help show stabil follow period us sale forc
disrupt compani solid track record commerci confid
abil get cynosur busi back growth full year
model cynosur revenu million flat sequenti manag note
revenu segment
march quarter histor season weaker aesthet
believ necessarili call q/q declin given tailwind new
product matur sale forc
gyn surgic revenu declin y/i ex-fx would
declin low single-digit adjust sell day manag continu see
strong perform myosur post ex-fx growth double-digit
adjust sell day said novasur weaken growth ex-fx
declin adjust sell day partial due tough comp
remind benefit competit product recal novasur
annual compani assum modest growth
skelet health revenu decreas y/i ex-fx million
manag note due lower fluoroscan sale though compani
expect quarterli sale improv cours year driven better portfolio
horizon bone densitometri system bodi
composit test new mini c-arm product
non-gaap ep increas y/i tax reform ad result tax
rate vs prior model ex tax benefit ep would come
midpoint guidanc
non-gaap ep growth
gross margin declin y/i driven primarili product
mix due blood screen divestitur divest blood screen busi carri
gross margin accret compani averag addit gross margin
impact complet quarter lower-margin cynosur product sale gross
margin expect remain similar level move forward cynosur
consum mix increas percentag revenu help margin
gross margin annual improv
oper margin declin y/i due divestitur blood screen
busi acquisit cynosur quarter oper margin
quarter declin y/i rel compani averag divest blood
screen busi higher margin cynosur margin dilut given
acquir asset commerci infrastructur oper expens pressur holog
oper margin go forward geograph mix also repres headwind
margin quarter sale market ex-comp came revenu
q/q expens revenu ex-comp q/q ex-
comp revenu declin y/i
adjust ex-comp sg trend
product revssg rev barclay holog inc
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
